

Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Takehiro Kawashiri¹, Daisuke Kobayashi¹, Mayako Uchida², Shiori Hiromoto¹, Masashi Inoue¹, Hajime Ikeda¹, Mizuki Inoue¹, Takao Shimazoe¹

¹Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan; ²Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

SUPPLEMENTS




Figure S2. Reporting odds ratios of leukemia in colorectal cancer. VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase




Figure S3. Reporting odds ratios of myelodysplastic syndromes in colorectal cancer. VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase




Figure S4. Reporting odds ratios for leukemia in gastric cancer. VEGF: vascular endothelial growth factor; HER: human epidermal growth factor receptor




Figure S5. Reporting odds ratios for myelodysplastic syndrome in gastric cancer. VEGF: vascular endothelial growth factor; HER: human epidermal growth factor receptor




Figure S6. Reporting odds ratios for leukemia in pancreatic cancer. VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin




Figure S7. Reporting odds ratios for myelodysplastic syndrome in pancreatic cancer. VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin




Figure S8. Reporting odds ratios for myelodysplastic syndrome in small cell lung cancer




Figure S9. Reporting odds ratios for leukemia in non-small cell lung cancer. VEGF, vascular endothelial growth factor; ALK, anaplastic lymphoma kinase; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase




Figure S10. Reporting odds ratios for myelodysplastic syndrome in non-small cell lung cancer. VEGF, vascular endothelial growth factor; ALK, anaplastic lymphoma kinase; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase




Figure S11. Reporting odds ratios for leukemia in esophageal cancer. EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor




Figure S12. Reporting odds ratios for myelodysplastic syndrome in esophageal cancer. EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor




Figure S13. Reporting odds ratios for leukemia in cervical cancer. VEGF: vascular endothelial growth factor




Figure S14. Reporting odds ratios for myelodysplastic syndrome in cervical cancer. VEGF: vascular endothelial growth factor